Adimmune Corp Cash Flow Conversion Efficiency
Adimmune Corp cash flow conversion efficiency. Based on the latest financial reports, Adimmune Corp (4142) has a cash flow conversion efficiency ratio of -0.073x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-355.08 Million ≈ $-11.19 Million USD) by net assets (NT$4.85 Billion ≈ $152.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Adimmune Corp (2007–2024)
Cash flow conversion efficiency of Adimmune Corp from 2007 to 2024. This chart illustrates how Adimmune Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Adimmune Corp stock quote for real-time trading data and today's change.
Adimmune Corp Cash Flow Conversion Ratio Explained
Adimmune Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Adimmune Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adimmune Corp ranked by their cash flow conversion efficiency. Also see Adimmune Corp stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bonava AB (publ)
ST:BONAV-B
|
-0.102x |
|
Nanning Baling Technology
SHE:002592
|
-0.008x |
|
Nampak
JSE:NPK
|
0.429x |
|
Clarke Inc.
TO:CKI
|
0.009x |
|
ANTENGENE CORP. DL-0001
F:722
|
N/A |
|
Real Asset Acquisition Corp.
NASDAQ:RAAQ
|
-0.001x |
|
Tivan Ltd
AU:TVN
|
-0.023x |
|
Alliance Entertainment Holding Corporation Class A Common Stock
NASDAQ:AENT
|
-0.077x |
Annual Cash Flow Conversion Efficiency for Adimmune Corp (2007–2024)
The table below shows the annual cash flow conversion efficiency of Adimmune Corp from 2007 to 2024. Review Adimmune Corp free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$5.56 Billion ≈ $175.22 Million |
NT$668.48 Million ≈ $21.06 Million |
0.120x | +177.82% |
| 2023-12-31 | NT$5.78 Billion ≈ $182.03 Million |
NT$-892.35 Million ≈ $-28.11 Million |
-0.154x | -246.22% |
| 2022-12-31 | NT$6.54 Billion ≈ $206.20 Million |
NT$-291.96 Million ≈ $-9.20 Million |
-0.045x | +40.28% |
| 2021-12-31 | NT$6.43 Billion ≈ $202.66 Million |
NT$-480.52 Million ≈ $-15.14 Million |
-0.075x | -121.33% |
| 2020-12-31 | NT$6.63 Billion ≈ $208.84 Million |
NT$2.32 Billion ≈ $73.15 Million |
0.350x | +630.21% |
| 2019-12-31 | NT$3.83 Billion ≈ $120.53 Million |
NT$-252.72 Million ≈ $-7.96 Million |
-0.066x | +79.62% |
| 2018-12-31 | NT$1.86 Billion ≈ $58.48 Million |
NT$-601.74 Million ≈ $-18.96 Million |
-0.324x | -11178.96% |
| 2017-12-31 | NT$2.35 Billion ≈ $74.02 Million |
NT$6.87 Million ≈ $216.57K |
0.003x | +101.17% |
| 2016-12-31 | NT$3.09 Billion ≈ $97.51 Million |
NT$-773.53 Million ≈ $-24.37 Million |
-0.250x | -146.38% |
| 2015-12-31 | NT$3.68 Billion ≈ $116.09 Million |
NT$-373.82 Million ≈ $-11.78 Million |
-0.101x | -8.59% |
| 2014-12-31 | NT$4.47 Billion ≈ $140.75 Million |
NT$-417.35 Million ≈ $-13.15 Million |
-0.093x | +46.82% |
| 2013-12-31 | NT$3.24 Billion ≈ $101.99 Million |
NT$-568.64 Million ≈ $-17.92 Million |
-0.176x | -60.56% |
| 2012-12-31 | NT$3.74 Billion ≈ $117.92 Million |
NT$-409.48 Million ≈ $-12.90 Million |
-0.109x | -34.00% |
| 2011-12-31 | NT$3.60 Billion ≈ $113.37 Million |
NT$-293.77 Million ≈ $-9.26 Million |
-0.082x | -164.23% |
| 2010-12-31 | NT$4.06 Billion ≈ $127.99 Million |
NT$516.39 Million ≈ $16.27 Million |
0.127x | -20.26% |
| 2009-12-31 | NT$3.77 Billion ≈ $118.67 Million |
NT$600.42 Million ≈ $18.92 Million |
0.159x | +472.28% |
| 2008-12-31 | NT$3.17 Billion ≈ $99.84 Million |
NT$-135.69 Million ≈ $-4.28 Million |
-0.043x | -363.61% |
| 2007-12-31 | NT$1.92 Billion ≈ $60.63 Million |
NT$31.26 Million ≈ $984.86K |
0.016x | -- |
About Adimmune Corp
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops Adim… Read more